RNA Targeting Small Molecule Drug Discovery Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Indication (Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases, Others), By End Users (Pharmaceutical and Biopharmaceutical Companies, Academic and Research Institutes, Others), By Region and Competition, 2020-2030F
Market Overview
The Global RNA Targeting Small Molecule Drug Discovery Market, valued at USD 1.68 billion in 2024, is projected treach USD 5.52 billion by 2030, growing at a CAGR of 21.93%. This growth is fueled by the increasing demand for RNA-targeted small molecule drugs capable of addressing a wide range of conditions, including cancer, neurological, and genetic disorders. Innovations in RNA-targeted drug discovery methods and heightened government support for RNA research are accelerating development in this field, attracting significant investments and interest across the pharmaceutical industry.
Key Market Drivers
Advancements in RNA Biology and Drug Discovery Technologies
Recent developments in RNA biology have revealed new RNA structures and functionalities as viable therapeutic targets. Tools like high-throughput sequencing and gene editing have significantly advanced the discovery of novel RNA targets and the creation of small molecules that can regulate RNA activity. These technological strides are streamlining drug development, making therapies more precise and effective. Moreover, the integration of computational methods and artificial intelligence is improving the prediction of RNA structures and interactions, thereby enhancing the efficiency of the discovery process. These advancements are driving increased pharmaceutical investment in RNA-targeted therapy.
Key Market Challenges
Complexity of RNA Structures and Target Specificity
Designing small molecules tselectively bind RNA targets is inherently challenging due tthe intricate secondary and tertiary structures of RNA molecules. Precision is vital tprevent unintended interactions with non-target RNAs, which could cause adverse effects. The flexible nature of RNA adds another layer of difficulty in identifying stable and effective binding sites. Overcoming these hurdles necessitates sophisticated structural analysis tools and innovative drug development strategies, which demand substantial time and resources.
Key Market Trends
Integration of Artificial Intelligence in Drug Discovery
Artificial Intelligence (AI) is playing a transformative role in the discovery of RNA-targeted small molecules. AI technologies are capable of analyzing large datasets tforecast RNA structures, locate potential binding regions, and simulate molecular behavior, which greatly accelerates candidate identification. This not only improves the precision and efficiency of development but alscuts down the time and expense compared ttraditional methods. As AI tools continue tevolve, their contribution tRNA-based therapeutic discovery is expected tgrow, paving new pathways for drug development.
Key Market Players
In this report, Global RNA Targeting Small Molecule Drug Discovery market has been segmented intthe following categories, in addition tthe industry trends which have alsbeen detailed below:
•??RNA Targeting Small Molecule Drug Discovery Market, By Indication:
Company Profiles: Detailed analysis of the major companies present in the Global RNA Targeting Small Molecule Drug Discovery Market.
Available Customizations:
With the given market data, TechSci Research offers customizations according ta company’s specific needs. The following customization options are available for the report:
Company Information
The Global RNA Targeting Small Molecule Drug Discovery Market, valued at USD 1.68 billion in 2024, is projected treach USD 5.52 billion by 2030, growing at a CAGR of 21.93%. This growth is fueled by the increasing demand for RNA-targeted small molecule drugs capable of addressing a wide range of conditions, including cancer, neurological, and genetic disorders. Innovations in RNA-targeted drug discovery methods and heightened government support for RNA research are accelerating development in this field, attracting significant investments and interest across the pharmaceutical industry.
Key Market Drivers
Advancements in RNA Biology and Drug Discovery Technologies
Recent developments in RNA biology have revealed new RNA structures and functionalities as viable therapeutic targets. Tools like high-throughput sequencing and gene editing have significantly advanced the discovery of novel RNA targets and the creation of small molecules that can regulate RNA activity. These technological strides are streamlining drug development, making therapies more precise and effective. Moreover, the integration of computational methods and artificial intelligence is improving the prediction of RNA structures and interactions, thereby enhancing the efficiency of the discovery process. These advancements are driving increased pharmaceutical investment in RNA-targeted therapy.
Key Market Challenges
Complexity of RNA Structures and Target Specificity
Designing small molecules tselectively bind RNA targets is inherently challenging due tthe intricate secondary and tertiary structures of RNA molecules. Precision is vital tprevent unintended interactions with non-target RNAs, which could cause adverse effects. The flexible nature of RNA adds another layer of difficulty in identifying stable and effective binding sites. Overcoming these hurdles necessitates sophisticated structural analysis tools and innovative drug development strategies, which demand substantial time and resources.
Key Market Trends
Integration of Artificial Intelligence in Drug Discovery
Artificial Intelligence (AI) is playing a transformative role in the discovery of RNA-targeted small molecules. AI technologies are capable of analyzing large datasets tforecast RNA structures, locate potential binding regions, and simulate molecular behavior, which greatly accelerates candidate identification. This not only improves the precision and efficiency of development but alscuts down the time and expense compared ttraditional methods. As AI tools continue tevolve, their contribution tRNA-based therapeutic discovery is expected tgrow, paving new pathways for drug development.
Key Market Players
- Accent Therapeutics, Inc.
- Anima Biotech Inc.
- Arrakis Therapeutics, Inc.
- AstraZeneca Plc
- Epics Therapeutics, Inc.
- Expansion Therapeutics, Inc.
- F. Hoffmann-La Roche AG
- H3 Biomedicine Inc.
- PTC Therapeutics, Inc.
- Ribometrix, Inc.
In this report, Global RNA Targeting Small Molecule Drug Discovery market has been segmented intthe following categories, in addition tthe industry trends which have alsbeen detailed below:
•??RNA Targeting Small Molecule Drug Discovery Market, By Indication:
- Cancer
- Infectious Diseases
- Metabolic Diseases
- Neurological Diseases
- Other
- Pharmaceutical and Biopharmaceutical Companies
- Academic and Research Institutes
- Others
- North America
- United States
- Canada
- Mexico
- Europe
- France
- Germany
- United Kingdom
- Italy
- Spain
- Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Company Profiles: Detailed analysis of the major companies present in the Global RNA Targeting Small Molecule Drug Discovery Market.
Available Customizations:
With the given market data, TechSci Research offers customizations according ta company’s specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up tfive).
1. PRODUCT OVERVIEW
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL RNA TARGETING SMALL MOLECULE DRUG DISCOVERY MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Indication (Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases, Others)
5.2.2. By End Users (Pharmaceutical and Biopharmaceutical Companies, Academic and Research Institutes, Others)
5.2.3. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
5.2.4. By Company (2024)
5.3. Market Map
5.3.1 By Indication
5.3.2 By End Users
5.3.3 By Region
6. NORTH AMERICA RNA TARGETING SMALL MOLECULE DRUG DISCOVERY MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Indication (Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases, Others)
6.2.2. By End Users (Pharmaceutical and Biopharmaceutical Companies, Academic and Research Institutes, Others)
6.2.3. By Country
6.3. North America: Country Analysis
6.3.1. United States RNA Targeting Small Molecule Drug Discovery Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Indication
6.3.1.2.2. By End User
6.3.2. Canada RNA Targeting Small Molecule Drug Discovery Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Indication
6.3.2.2.2. By End User
6.3.3. Mexico RNA Targeting Small Molecule Drug Discovery Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Indication
6.3.3.2.2. By End User
7. EUROPE RNA TARGETING SMALL MOLECULE DRUG DISCOVERY MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Indication (Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases, Others)
7.2.2. By End Users (Pharmaceutical and Biopharmaceutical Companies, Academic and Research Institutes, Others)
7.2.3. By Country
7.3. Europe: Country Analysis
7.3.1. France RNA Targeting Small Molecule Drug Discovery Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Indication
7.3.1.2.2. By End User
7.3.2. Germany RNA Targeting Small Molecule Drug Discovery Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Indication
7.3.2.2.2. By End User
7.3.3. United Kingdom RNA Targeting Small Molecule Drug Discovery Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Indication
7.3.3.2.2. By End User
7.3.4. Italy RNA Targeting Small Molecule Drug Discovery Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Indication
7.3.4.2.2. By End User
7.3.5. Spain RNA Targeting Small Molecule Drug Discovery Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Indication
7.3.5.2.2. By End User
8. ASIA-PACIFIC RNA TARGETING SMALL MOLECULE DRUG DISCOVERY MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Indication (Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases, Others)
8.2.2. By End Users (Pharmaceutical and Biopharmaceutical Companies, Academic and Research Institutes, Others)
8.2.3. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China RNA Targeting Small Molecule Drug Discovery Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Indication
8.3.1.2.2. By End User
8.3.2. India RNA Targeting Small Molecule Drug Discovery Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Indication
8.3.2.2.2. By End User
8.3.3. Japan RNA Targeting Small Molecule Drug Discovery Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Indication
8.3.3.2.2. By End User
8.3.4. South Korea RNA Targeting Small Molecule Drug Discovery Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Indication
8.3.4.2.2. By End User
8.3.5. Australia RNA Targeting Small Molecule Drug Discovery Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Indication
8.3.5.2.2. By End User
9. SOUTH AMERICA RNA TARGETING SMALL MOLECULE DRUG DISCOVERY MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Indication (Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases, Others)
9.2.2. By End Users (Pharmaceutical and Biopharmaceutical Companies, Academic and Research Institutes, Others)
9.2.3. By Country
9.3. South America: Country Analysis
9.3.1. Brazil RNA Targeting Small Molecule Drug Discovery Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Indication
9.3.1.2.2. By End User
9.3.2. Argentina RNA Targeting Small Molecule Drug Discovery Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Indication
9.3.2.2.2. By End User
9.3.3. Colombia RNA Targeting Small Molecule Drug Discovery Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Indication
9.3.3.2.2. By End User
10. MIDDLE EAST AND AFRICA RNA TARGETING SMALL MOLECULE DRUG DISCOVERY MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Indication (Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases, Others)
10.2.2. By End Users (Pharmaceutical and Biopharmaceutical Companies, Academic and Research Institutes, Others)
10.2.3. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa RNA Targeting Small Molecule Drug Discovery Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Indication
10.3.1.2.2. By End User
10.3.2. Saudi Arabia RNA Targeting Small Molecule Drug Discovery Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Indication
10.3.2.2.2. By End User
10.3.3. UAE RNA Targeting Small Molecule Drug Discovery Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Indication
10.3.3.2.2. By End User
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Recent Development
12.2. Mergers & Acquisitions
12.3. Product Launches
13. GLOBAL RNA TARGETING SMALL MOLECULE DRUG DISCOVERY MARKET: SWOT ANALYSIS
14. PORTER’S FIVE FORCES ANALYSIS
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. COMPETITIVE LANDSCAPE
15.1. Accent Therapeutics, Inc.
15.1.1. Business Overview
15.1.2. Company Snapshot
15.1.3. Products & Services
15.1.4. Financials (As Reported)
15.1.5. Recent Developments
15.1.6. Key Personnel Details
15.1.7. SWOT Analysis
15.2. Anima Biotech Inc.
15.3. Arrakis Therapeutics, Inc.
15.4. AstraZeneca Plc
15.5. Epics Therapeutics, Inc.
15.6. Expansion Therapeutics, Inc.
15.7. F.Hoffmann-La Roche AG
15.8. H3 Biomedicine Inc.
15.9. PTC Therapeutics, Inc.
15.10. Ribometrix, Inc.
16. STRATEGIC RECOMMENDATIONS
17. ABOUT US & DISCLAIMER
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL RNA TARGETING SMALL MOLECULE DRUG DISCOVERY MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Indication (Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases, Others)
5.2.2. By End Users (Pharmaceutical and Biopharmaceutical Companies, Academic and Research Institutes, Others)
5.2.3. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
5.2.4. By Company (2024)
5.3. Market Map
5.3.1 By Indication
5.3.2 By End Users
5.3.3 By Region
6. NORTH AMERICA RNA TARGETING SMALL MOLECULE DRUG DISCOVERY MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Indication (Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases, Others)
6.2.2. By End Users (Pharmaceutical and Biopharmaceutical Companies, Academic and Research Institutes, Others)
6.2.3. By Country
6.3. North America: Country Analysis
6.3.1. United States RNA Targeting Small Molecule Drug Discovery Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Indication
6.3.1.2.2. By End User
6.3.2. Canada RNA Targeting Small Molecule Drug Discovery Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Indication
6.3.2.2.2. By End User
6.3.3. Mexico RNA Targeting Small Molecule Drug Discovery Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Indication
6.3.3.2.2. By End User
7. EUROPE RNA TARGETING SMALL MOLECULE DRUG DISCOVERY MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Indication (Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases, Others)
7.2.2. By End Users (Pharmaceutical and Biopharmaceutical Companies, Academic and Research Institutes, Others)
7.2.3. By Country
7.3. Europe: Country Analysis
7.3.1. France RNA Targeting Small Molecule Drug Discovery Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Indication
7.3.1.2.2. By End User
7.3.2. Germany RNA Targeting Small Molecule Drug Discovery Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Indication
7.3.2.2.2. By End User
7.3.3. United Kingdom RNA Targeting Small Molecule Drug Discovery Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Indication
7.3.3.2.2. By End User
7.3.4. Italy RNA Targeting Small Molecule Drug Discovery Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Indication
7.3.4.2.2. By End User
7.3.5. Spain RNA Targeting Small Molecule Drug Discovery Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Indication
7.3.5.2.2. By End User
8. ASIA-PACIFIC RNA TARGETING SMALL MOLECULE DRUG DISCOVERY MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Indication (Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases, Others)
8.2.2. By End Users (Pharmaceutical and Biopharmaceutical Companies, Academic and Research Institutes, Others)
8.2.3. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China RNA Targeting Small Molecule Drug Discovery Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Indication
8.3.1.2.2. By End User
8.3.2. India RNA Targeting Small Molecule Drug Discovery Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Indication
8.3.2.2.2. By End User
8.3.3. Japan RNA Targeting Small Molecule Drug Discovery Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Indication
8.3.3.2.2. By End User
8.3.4. South Korea RNA Targeting Small Molecule Drug Discovery Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Indication
8.3.4.2.2. By End User
8.3.5. Australia RNA Targeting Small Molecule Drug Discovery Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Indication
8.3.5.2.2. By End User
9. SOUTH AMERICA RNA TARGETING SMALL MOLECULE DRUG DISCOVERY MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Indication (Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases, Others)
9.2.2. By End Users (Pharmaceutical and Biopharmaceutical Companies, Academic and Research Institutes, Others)
9.2.3. By Country
9.3. South America: Country Analysis
9.3.1. Brazil RNA Targeting Small Molecule Drug Discovery Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Indication
9.3.1.2.2. By End User
9.3.2. Argentina RNA Targeting Small Molecule Drug Discovery Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Indication
9.3.2.2.2. By End User
9.3.3. Colombia RNA Targeting Small Molecule Drug Discovery Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Indication
9.3.3.2.2. By End User
10. MIDDLE EAST AND AFRICA RNA TARGETING SMALL MOLECULE DRUG DISCOVERY MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Indication (Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases, Others)
10.2.2. By End Users (Pharmaceutical and Biopharmaceutical Companies, Academic and Research Institutes, Others)
10.2.3. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa RNA Targeting Small Molecule Drug Discovery Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Indication
10.3.1.2.2. By End User
10.3.2. Saudi Arabia RNA Targeting Small Molecule Drug Discovery Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Indication
10.3.2.2.2. By End User
10.3.3. UAE RNA Targeting Small Molecule Drug Discovery Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Indication
10.3.3.2.2. By End User
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Recent Development
12.2. Mergers & Acquisitions
12.3. Product Launches
13. GLOBAL RNA TARGETING SMALL MOLECULE DRUG DISCOVERY MARKET: SWOT ANALYSIS
14. PORTER’S FIVE FORCES ANALYSIS
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. COMPETITIVE LANDSCAPE
15.1. Accent Therapeutics, Inc.
15.1.1. Business Overview
15.1.2. Company Snapshot
15.1.3. Products & Services
15.1.4. Financials (As Reported)
15.1.5. Recent Developments
15.1.6. Key Personnel Details
15.1.7. SWOT Analysis
15.2. Anima Biotech Inc.
15.3. Arrakis Therapeutics, Inc.
15.4. AstraZeneca Plc
15.5. Epics Therapeutics, Inc.
15.6. Expansion Therapeutics, Inc.
15.7. F.Hoffmann-La Roche AG
15.8. H3 Biomedicine Inc.
15.9. PTC Therapeutics, Inc.
15.10. Ribometrix, Inc.
16. STRATEGIC RECOMMENDATIONS
17. ABOUT US & DISCLAIMER
